Oxford NanoLabs Ltd Receives Funding From IP2IPO

Funding Rounds

▤ Summary

Its “NanoPore”technology is based on using protein pores for the highly sensitive detection of a range of medically important molecules. ONL’s objective is to develop a series of products from its platform technology, initially hand-held diagnostic devices for medical testing with longer-term applications in counter-bioterrorism and gene sequencing. After a spell in academia, Dr Sanghera began his commercial career at Medisense, an Oxford-based company that was sold to Abbot Laboratories in 1996 for £876m. Commenting on today’s announcement, Dr Sanghera, Chief Executive Officer of ONL said, “The NanoPore technology has the potential to revolutionise the diagnostic world. The Medisense experience shows just how valuable a breakthrough in point of care medical diagnostics can become and I am delighted to be part of such an exciting opportunity.”

$ Funding

$
Amount $891.5K Total raised
□
Date May 23, 2005 Announcement date
◎
Investors Oxford Nanopore Technologies, IP Group Lead investors
▥
Company http://www.nanoporetech.com Funded company

▥ Classifications

industries
No industries detected
applications
Data Management

◇ AskAI Classifications

Labels
Biotechnology Software SaaS

▦ Linked Companies